Phase I EGFR BATs in Newly Diagnosed Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

December 8, 2021

Study Completion Date

May 8, 2023

Conditions
GlioblastomaGlioblastoma Multiforme
Interventions
DRUG

EGFR BATs with TMZ following SOC RT/TMZ

Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.

DRUG

Weekly EGFR BATs following SOC RT/TMZ

Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ

Trial Locations (1)

22908

Samantha Brooks, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER

NCT03344250 - Phase I EGFR BATs in Newly Diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter